Retrospective analysis of children diagnosed with Kawasaki disease

Background/aim: The aim of our study was to evaluate the long-term impacts of Kawasaki disease on our patients regarding coronary involvement demographic characteristics, treatment regimens, and clinical course. Materials and methods: Our study included 104 patients diagnosed and hospitalized with Kawasaki disease in our center, from January 2004 to January 2019. In our study, patients were divided into three groups according to coronary artery involvement. Patients in group 1 had no echocardiographic findings, while the ones in group 2 had coronary artery dilatation and ones in group 3 had coronary artery aneurysm (CAA). Results: Among 104 patients, the median age was 9.15 (3.0–22.0) years, and 61 of the patients were male while 43 of the patients were female. With a wide range of 1.50–16.50 years of follow-up time, the median diagnosis age of our patients was 31 months (3.0–164.0). Fever duration (median day 10 (5–21), p = 0.025) was statistically significantly higher in group 3. Blood C-reactive protein (CRP) levels, white blood cell (WBC) counts, and neutrophil counts were significantly higher in group 3. There was a statistically significant difference between patients in group 3 and group 2 in which the lowest strain deformation values were in the patients of group 3. In contrast to group 1, the time for initiation of IVIG therapy is significantly prolonged both in group 2 (median: 9.5 days, p = 0.028) and group 3 (median: 10 days, p = 0.036). Conclusion: In our study, serum CRP levels, WBC count, and neutrophil count were higher in patients with coronary artery abnormalities, in agreement with the previous studies. In the light of our results, we consider that the most important determining factor for the development of coronary artery aneurysm is the time of intravenous immunoglobulin (IVIG) administration.

[1]  M. Segelmark,et al.  High risk of coronary artery aneurysm in Kawasaki disease , 2020, Rheumatology.

[2]  Colin G Fink,et al.  Biomarkers for the Discrimination of Acute Kawasaki Disease From Infections in Childhood , 2020, Frontiers in Pediatrics.

[3]  Haobo Weng,et al.  Decreased serum Annexin A1 levels in Kawasaki disease with coronary artery aneurysm , 2020, Pediatric Research.

[4]  Jie Tian,et al.  Risk Factors of Coronary Artery Abnormality in Children With Kawasaki Disease: A Systematic Review and Meta-Analysis , 2019, Front. Pediatr..

[5]  K. Gauvreau,et al.  Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population , 2019, Journal of the American Heart Association.

[6]  L. Jung,et al.  Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition , 2019, Pediatric Rheumatology.

[7]  T. Tsuchihashi,et al.  Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. , 2018, The Lancet. Child & adolescent health.

[8]  L. B. Gámez-González,et al.  Kawasaki disease shock syndrome: Unique and severe subtype of Kawasaki disease , 2018, Pediatrics international : official journal of the Japan Pediatric Society.

[9]  J. Ashworth,et al.  Role of C-Reactive Protein at Sites of Inflammation and Infection , 2018, Front. Immunol..

[10]  Yosikazu Nakamura,et al.  Kawasaki disease: epidemiology and the lessons from it , 2017, International journal of rheumatic diseases.

[11]  T. Kuijpers,et al.  Giant aneurysms: A gender-specific complication of Kawasaki disease? , 2017, Journal of cardiology.

[12]  B. McCrindle,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association , 2017, Circulation.

[13]  O. Kasapcopur,et al.  Evaluation of myocardial deformation in patients with Kawasaki disease using speckle-tracking echocardiography during mid-term follow-up , 2017, Cardiology in the Young.

[14]  Fangqi Gong,et al.  Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease , 2017, Pediatric Rheumatology.

[15]  M. Song,et al.  Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease , 2016, Korean journal of pediatrics.

[16]  O. Kasapcopur,et al.  Pediatric vasculitis , 2016, Current opinion in rheumatology.

[17]  A. Petrova,et al.  Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease. , 2014, Pediatrics and neonatology.

[18]  R. Uehara,et al.  Late Intravenous Immunoglobulin Treatment in Patients With Kawasaki Disease , 2012, Pediatrics.

[19]  J. Burns,et al.  Evolution of Laboratory Values in Patients With Kawasaki Disease , 2011, The Pediatric infectious disease journal.

[20]  Victor Mor-Avi,et al.  Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. , 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[21]  Victor Mor-Avi,et al.  Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[22]  B. McCrindle,et al.  Comparison of factors associated with coronary artery dilation only versus coronary artery aneurysms in patients with Kawasaki disease. , 2009, The American journal of cardiology.

[23]  Andrew M Kahn,et al.  When children with Kawasaki disease grow up: Myocardial and vascular complications in adulthood. , 2009, Journal of the American College of Cardiology.

[24]  JungHwa Lee,et al.  Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor , 2009, European Journal of Pediatrics.

[25]  R. Uehara,et al.  Epidemiologic Features of Kawasaki Disease in Japan: Results from the Nationwide Survey in 2005-2006 , 2008, Journal of epidemiology.

[26]  Xiao-hui Li,et al.  Epidemiological survey of Kawasaki disease in Sichuan province of China. , 2007, Journal of tropical pediatrics.

[27]  Tomio Kobayashi,et al.  Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients With Kawasaki Disease , 2006, Circulation.

[28]  P. Lysyansky,et al.  Global longitudinal strain: a novel index of left ventricular systolic function. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[29]  H. Yanagawa,et al.  Leukocyte counts in patients with Kawasaki disease: from the results of nationwide surveys of Kawasaki disease in Japan , 1997, Acta paediatrica.

[30]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[31]  Katsuko Sato,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[32]  R. Alizadeh-Navaei,et al.  Comparison of early and late intravenous gamma globulin treatment of Kawasaki disease on fever and cardiovascular complications , 2016, Caspian journal of internal medicine.

[33]  Nagib Dahdah,et al.  New equations and a critical appraisal of coronary artery Z scores in healthy children. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[34]  C. Rey,et al.  Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children , 2007, Intensive Care Medicine.

[35]  P. Salamati,et al.  RELATIONSHIP BETWEEN ESR, CRP, PLATELET COUNT AND CORONARY ARTERY DISEASE IN KAWASAKI DISEASE , 2005 .

[36]  M. Mori,et al.  Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. , 2000, The Journal of pediatrics.

[37]  R Gorlin,et al.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. , 1976, The American journal of cardiology.